Home › Companies › LINEAGE CELL THERAPEUTICS INC. › 2024-2025

LINEAGE CELL THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and LINEAGE CELL THERAPEUTICS INC.’s Form 8-K, filed 2025-07-02 (Item 5.07 on EDGAR). Page generated 04 October 2026.

13Reported items
120Asset managers
934Fund votes
2025-06-26Main meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore LINEAGE CELL THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by LINEAGE CELL THERAPEUTICS INC.

These tallies are LINEAGE CELL THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-07-02 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. LINEAGE CELL THERAPEUTICS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

LINEAGE CELL THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-26 (Form 8-K, filed 2025-07-02)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Michael H. Mulroy	99,312,637	--	--	1,174,790	59,813,557	Majority: yes
Elect Director: Dipti Amin	99,362,438	--	--	1,124,989	59,813,557	Majority: yes
Elect Director: Deborah Andrews	98,593,393	--	--	1,894,034	59,813,557	Majority: yes
Elect Director: Angus C. Russell	99,373,222	--	--	1,114,205	59,813,557	Majority: yes
Elect Director: Neal C. Bradsher	98,861,237	--	--	1,626,190	59,813,557	Majority: yes
Elect Director: Brian M. Culley	98,593,167	--	--	1,894,260	59,813,557	Majority: yes
Elect Director: Anula Jayasuriya	99,077,018	--	--	1,410,409	59,813,557	Majority: yes
Proposal 2: Shareholders ratified the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 by the following votes:	158,952,692	912,282	436,010	--	--	Majority: yes
Proposal 3: Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes:	96,071,162	3,804,451	611,814	--	59,813,557	Passed
Proposal 4: Shareholders approved the EIP Amendment by the votes set forth below.:	88,575,737	11,560,925	350,765	--	59,813,557	Passed

Source: LINEAGE CELL THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-07-02 — read the filing on EDGAR.

LINEAGE CELL THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-01-27 (Form 8-K, filed 2025-01-27)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 2: Shareholders approved the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of proposal 1 if there were not sufficient votes to approve such proposal at the time of the meeting or any adjournment or postp	112,392,014	8,458,712	375,748	--	0	Passed

Source: LINEAGE CELL THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-01-27 — read the filing on EDGAR.

How asset managers voted at the LINEAGE CELL THERAPEUTICS INC. 2024-2025 meetings

Each item below shows how the 120 asset managers that disclosed a LINEAGE CELL THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of LINEAGE CELL THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Meeting held 2025-06-26.

Combines 9 wordings of this item as funds reported it.

96% Passed · of votes cast

FOR 96%

FOR: 96,071,162AGAINST: 3,804,451

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes:”): 96,071,162 for, 3,804,451 against — passed, per its Form 8-K filed 2025-07-02 (Item 5.07). Of all 228,356,290 outstanding shares: 42% for, 2% against (44% of the company cast a for/against vote).

The 116 asset managers below cast 98% of the shares they voted on this item FOR (30,138,016 for, 524,939 against).

FOR 98%

FOR: 30,138,016 (98.3%)AGAINST: 524,939 (1.7%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
RAFFLES ASSOCIATES LP	5,642,088	0	For
COMERICA BANK	4,000,000	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,375,807	0	For
Fidelity	3,100,560	0	For
Vanguard	2,659,102	0	For
DAFNA Capital Management LLC	2,511,374	0	For
BlackRock	2,263,253	0	For
State Street	1,236,382	0	For
Charles Schwab	1,006,386	0	For
Northern Trust	928,518	0	For
MELLON INVESTMENTS Corp	497,938	0	For
Phoenix Financial Ltd.	0	479,350	Against
RBC Capital Markets, LLC	437,028	0	For
Two Sigma	383,277	0	For
QUANTITATIVE MASTER SERIES LLC	291,019	0	For
Prescott General Partners LLC	262,000	0	For
STIFEL NICOLAUS & CO INC \MO\	135,059	0	For
Lincoln Financial	124,500	4,300	For
Global X	105,098	0	For
AIG/SunAmerica	94,050	0	For
Equitable	84,962	0	For
JPMorgan	81,248	0	For
Voya	77,670	0	For
Pacific Life	66,912	0	For
Rhumbline	58,723	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

2. TO APPROVE THE ADJOURNMENT OF THE MEETING, IF NECESSARY OR ADVISABLE, TO SOLICIT ADDITIONAL PROXIES IN FAVOR OF THE FOREGOING PROPOSAL IF THERE ARE NOT SUFFICIENT VOTES TO APPROVE SUCH PROPOSAL AT THE TIME OF THE MEETING OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF.

CORPORATE GOVERNANCECompany result: Passed

Meeting held 2025-01-27.

93% Passed · of votes cast

FOR 93%

FOR: 112,392,014AGAINST: 8,458,712

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Shareholders approved the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of proposal 1 if there were not sufficient votes to approve such proposal at the time of”): 112,392,014 for, 8,458,712 against — passed, per its Form 8-K filed 2025-01-27 (Item 5.07). Of all 228,356,290 outstanding shares: 49.2% for, 4% against (52.9% of the company cast a for/against vote).

The 29 asset managers below cast 98% of the shares they voted on this item FOR (13,904,685 for, 246,173 against).

FOR 98%

FOR: 13,904,685 (98.3%)AGAINST: 246,173 (1.7%)

Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE MEETING, IF NECESSARY OR ADVISABLE, TO SOLICIT ADDITIONAL PROXIES IN FAVOR O” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	8,286,793	0	For
BlackRock	2,786,683	0	For
Fidelity	1,408,438	0	For
Charles Schwab	416,223	0	For
BRIDGEWAY FUNDS INC	360,685	0	For
Lincoln Financial	4,300	124,500	Against
Equitable	119,670	0	For
Global X	81,445	0	For
T. Rowe Price	0	66,979	Against
Pacific Life	66,327	0	For
TIAA	62,808	0	For
State Street	0	47,331	Against
QUANTITATIVE MASTER SERIES LLC	44,600	0	For
ProShares	42,841	0	For
Northern Trust	39,931	0	For
Voya	38,835	0	For
John Hancock	32,559	0	For
AIG/SunAmerica	31,518	0	For
Bridge Builder Trust	31,143	0	For
DWS	19,932	0	For
Calvert	10,656	0	For
Victory Capital	7,443	0	For
PENN SERIES FUNDS INC	0	5,100	Against
Jackson National	4,400	0	For
Morgan Stanley	4,062	0	For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

3. To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-26.

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 99,373,222WITHHELD: 1,114,205

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Angus C. Russell”): 99,373,222 for, 1,114,205 withheld, per its Form 8-K filed 2025-07-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 228,356,290 outstanding shares: 44% for, 0.5% withheld (44% of the company cast a for/withheld vote).

The 28 asset managers below cast 100% of the shares they voted on this item FOR (7,246,255 for, 0 against).

FOR 100%

FOR: 7,246,255 (100.0%)

Largest asset managers voting on “To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Fidelity	2,905,515	For
Vanguard	2,395,702	For
Charles Schwab	503,193	For
BlackRock	342,508	For
QUANTITATIVE MASTER SERIES LLC	291,019	For
Lincoln Financial	128,800	For
Global X	105,098	For
Northern Trust	96,314	For
AIG/SunAmerica	94,050	For
Equitable	84,962	For
Pacific Life	66,912	For
Bridge Builder Trust	41,529	For
Voya	38,835	For
ProShares	32,821	For
Columbia Threadneedle	23,397	For
Victory Capital	22,856	For
DWS	22,379	For
Calvert	10,656	For
State Street	8,516	For
Goldman Sachs	6,462	For
John Hancock	6,217	For
TIAA	5,156	For
PENN SERIES FUNDS INC	5,100	For
Blackstone Alternative Investment Funds	3,700	For
Brinker Capital Destinations Trust	2,263	For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

4. To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-26.

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 99,077,018WITHHELD: 1,410,409

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anula Jayasuriya”): 99,077,018 for, 1,410,409 withheld, per its Form 8-K filed 2025-07-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 228,356,290 outstanding shares: 43% for, 0.7% withheld (44% of the company cast a for/withheld vote).

The 28 asset managers below cast 100% of the shares they voted on this item FOR (7,246,255 for, 0 against).

FOR 100%

FOR: 7,246,255 (100.0%)

Largest asset managers voting on “To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Fidelity	2,905,515	For
Vanguard	2,395,702	For
Charles Schwab	503,193	For
BlackRock	342,508	For
QUANTITATIVE MASTER SERIES LLC	291,019	For
Lincoln Financial	128,800	For
Global X	105,098	For
Northern Trust	96,314	For
AIG/SunAmerica	94,050	For
Equitable	84,962	For
Pacific Life	66,912	For
Bridge Builder Trust	41,529	For
Voya	38,835	For
ProShares	32,821	For
Columbia Threadneedle	23,397	For
Victory Capital	22,856	For
DWS	22,379	For
Calvert	10,656	For
State Street	8,516	For
Goldman Sachs	6,462	For
John Hancock	6,217	For
TIAA	5,156	For
PENN SERIES FUNDS INC	5,100	For
Blackstone Alternative Investment Funds	3,700	For
Brinker Capital Destinations Trust	2,263	For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

5. To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-26.

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 98,593,167WITHHELD: 1,894,260

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Brian M. Culley”): 98,593,167 for, 1,894,260 withheld, per its Form 8-K filed 2025-07-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 228,356,290 outstanding shares: 43% for, 0.9% withheld (44% of the company cast a for/withheld vote).

The 28 asset managers below cast 100% of the shares they voted on this item FOR (7,246,255 for, 0 against).

FOR 100%

FOR: 7,246,255 (100.0%)

Largest asset managers voting on “To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Fidelity	2,905,515	For
Vanguard	2,395,702	For
Charles Schwab	503,193	For
BlackRock	342,508	For
QUANTITATIVE MASTER SERIES LLC	291,019	For
Lincoln Financial	128,800	For
Global X	105,098	For
Northern Trust	96,314	For
AIG/SunAmerica	94,050	For
Equitable	84,962	For
Pacific Life	66,912	For
Bridge Builder Trust	41,529	For
Voya	38,835	For
ProShares	32,821	For
Columbia Threadneedle	23,397	For
Victory Capital	22,856	For
DWS	22,379	For
Calvert	10,656	For
State Street	8,516	For
Goldman Sachs	6,462	For
John Hancock	6,217	For
TIAA	5,156	For
PENN SERIES FUNDS INC	5,100	For
Blackstone Alternative Investment Funds	3,700	For
Brinker Capital Destinations Trust	2,263	For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

6. To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-26.

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 98,593,393WITHHELD: 1,894,034

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Deborah Andrews”): 98,593,393 for, 1,894,034 withheld, per its Form 8-K filed 2025-07-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 228,356,290 outstanding shares: 43% for, 0.9% withheld (44% of the company cast a for/withheld vote).

The 28 asset managers below cast 100% of the shares they voted on this item FOR (7,246,255 for, 0 against).

FOR 100%

FOR: 7,246,255 (100.0%)

Largest asset managers voting on “To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Fidelity	2,905,515	For
Vanguard	2,395,702	For
Charles Schwab	503,193	For
BlackRock	342,508	For
QUANTITATIVE MASTER SERIES LLC	291,019	For
Lincoln Financial	128,800	For
Global X	105,098	For
Northern Trust	96,314	For
AIG/SunAmerica	94,050	For
Equitable	84,962	For
Pacific Life	66,912	For
Bridge Builder Trust	41,529	For
Voya	38,835	For
ProShares	32,821	For
Columbia Threadneedle	23,397	For
Victory Capital	22,856	For
DWS	22,379	For
Calvert	10,656	For
State Street	8,516	For
Goldman Sachs	6,462	For
John Hancock	6,217	For
TIAA	5,156	For
PENN SERIES FUNDS INC	5,100	For
Blackstone Alternative Investment Funds	3,700	For
Brinker Capital Destinations Trust	2,263	For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

7. To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-26.

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 99,362,438WITHHELD: 1,124,989

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dipti Amin”): 99,362,438 for, 1,124,989 withheld, per its Form 8-K filed 2025-07-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 228,356,290 outstanding shares: 44% for, 0.5% withheld (44% of the company cast a for/withheld vote).

The 28 asset managers below cast 100% of the shares they voted on this item FOR (7,246,255 for, 0 against).

FOR 100%

FOR: 7,246,255 (100.0%)

Largest asset managers voting on “To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Fidelity	2,905,515	For
Vanguard	2,395,702	For
Charles Schwab	503,193	For
BlackRock	342,508	For
QUANTITATIVE MASTER SERIES LLC	291,019	For
Lincoln Financial	128,800	For
Global X	105,098	For
Northern Trust	96,314	For
AIG/SunAmerica	94,050	For
Equitable	84,962	For
Pacific Life	66,912	For
Bridge Builder Trust	41,529	For
Voya	38,835	For
ProShares	32,821	For
Columbia Threadneedle	23,397	For
Victory Capital	22,856	For
DWS	22,379	For
Calvert	10,656	For
State Street	8,516	For
Goldman Sachs	6,462	For
John Hancock	6,217	For
TIAA	5,156	For
PENN SERIES FUNDS INC	5,100	For
Blackstone Alternative Investment Funds	3,700	For
Brinker Capital Destinations Trust	2,263	For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

8. To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-26.

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 99,312,637WITHHELD: 1,174,790

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael H. Mulroy”): 99,312,637 for, 1,174,790 withheld, per its Form 8-K filed 2025-07-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 228,356,290 outstanding shares: 43% for, 0.6% withheld (44% of the company cast a for/withheld vote).

The 28 asset managers below cast 100% of the shares they voted on this item FOR (7,235,599 for, 0 against).

FOR 99.8%

FOR: 7,235,599 (99.9%)ABSTAIN: 10,656 (0.1%)

Largest asset managers voting on “To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	2,905,515	0	For
Vanguard	2,395,702	0	For
Charles Schwab	503,193	0	For
BlackRock	342,508	0	For
QUANTITATIVE MASTER SERIES LLC	291,019	0	For
Lincoln Financial	128,800	0	For
Global X	105,098	0	For
Northern Trust	96,314	0	For
AIG/SunAmerica	94,050	0	For
Equitable	84,962	0	For
Pacific Life	66,912	0	For
Bridge Builder Trust	41,529	0	For
Voya	38,835	0	For
ProShares	32,821	0	For
Columbia Threadneedle	23,397	0	For
Victory Capital	22,856	0	For
DWS	22,379	0	For
Calvert	0	10,656	Abstain
State Street	8,516	0	For
Goldman Sachs	6,462	0	For
John Hancock	6,217	0	For
TIAA	5,156	0	For
PENN SERIES FUNDS INC	5,100	0	For
Blackstone Alternative Investment Funds	3,700	0	For
Brinker Capital Destinations Trust	2,263	0	For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

9. To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-26.

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 98,861,237WITHHELD: 1,626,190

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Neal C. Bradsher”): 98,861,237 for, 1,626,190 withheld, per its Form 8-K filed 2025-07-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 228,356,290 outstanding shares: 43% for, 0.8% withheld (44% of the company cast a for/withheld vote).

The 28 asset managers below cast 100% of the shares they voted on this item FOR (7,235,599 for, 0 against).

FOR 99.8%

FOR: 7,235,599 (99.9%)ABSTAIN: 10,656 (0.1%)

Largest asset managers voting on “To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	2,905,515	0	For
Vanguard	2,395,702	0	For
Charles Schwab	503,193	0	For
BlackRock	342,508	0	For
QUANTITATIVE MASTER SERIES LLC	291,019	0	For
Lincoln Financial	128,800	0	For
Global X	105,098	0	For
Northern Trust	96,314	0	For
AIG/SunAmerica	94,050	0	For
Equitable	84,962	0	For
Pacific Life	66,912	0	For
Bridge Builder Trust	41,529	0	For
Voya	38,835	0	For
ProShares	32,821	0	For
Columbia Threadneedle	23,397	0	For
Victory Capital	22,856	0	For
DWS	22,379	0	For
Calvert	0	10,656	Abstain
State Street	8,516	0	For
Goldman Sachs	6,462	0	For
John Hancock	6,217	0	For
TIAA	5,156	0	For
PENN SERIES FUNDS INC	5,100	0	For
Blackstone Alternative Investment Funds	3,700	0	For
Brinker Capital Destinations Trust	2,263	0	For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

10. To approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of common shares available thereunder by 19,500,000.

COMPENSATION

Meeting held 2025-06-26.

92% fund support · no official result

FOR 92%8%

The 28 asset managers below cast 92% of the shares they voted on this item FOR (6,695,021 for, 551,234 against).

FOR: 6,695,021 (92.4%)AGAINST: 551,234 (7.6%)

Largest asset managers voting on “To approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan to increase the numb” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	2,905,515	0	For
Vanguard	2,395,702	0	For
Charles Schwab	503,193	0	For
BlackRock	342,508	0	For
QUANTITATIVE MASTER SERIES LLC	291,019	0	For
Lincoln Financial	0	128,800	Against
Global X	105,098	0	For
Northern Trust	0	96,314	Against
AIG/SunAmerica	0	94,050	Against
Equitable	38,382	46,580	Against
Pacific Life	66,912	0	For
Bridge Builder Trust	41,529	0	For
Voya	0	38,835	Against
ProShares	0	32,821	Against
Columbia Threadneedle	0	23,397	Against
Victory Capital	0	22,856	Against
DWS	0	22,379	Against
Calvert	0	10,656	Against
State Street	0	8,516	Against
Goldman Sachs	0	6,462	Against
John Hancock	0	6,217	Against
TIAA	5,156	0	For
PENN SERIES FUNDS INC	0	5,100	Against
Blackstone Alternative Investment Funds	0	3,700	Against
Brinker Capital Destinations Trust	0	2,263	Against

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

11. To ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-26.

Combines 2 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 158,952,692AGAINST: 912,282

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Shareholders ratified the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 by the following votes:”): 158,952,692 for, 912,282 against, per its Form 8-K filed 2025-07-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 228,356,290 outstanding shares: 70% for, 0.4% against (70% of the company cast a for/against vote).

The 28 asset managers below cast 100% of the shares they voted on this item FOR (7,246,255 for, 0 against).

FOR 100%

FOR: 7,246,255 (100.0%)

Largest asset managers voting on “To ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for our fisca” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Fidelity	2,905,515	For
Vanguard	2,395,702	For
Charles Schwab	503,193	For
BlackRock	342,508	For
QUANTITATIVE MASTER SERIES LLC	291,019	For
Lincoln Financial	128,800	For
Global X	105,098	For
Northern Trust	96,314	For
AIG/SunAmerica	94,050	For
Equitable	84,962	For
Pacific Life	66,912	For
Bridge Builder Trust	41,529	For
Voya	38,835	For
ProShares	32,821	For
Columbia Threadneedle	23,397	For
Victory Capital	22,856	For
DWS	22,379	For
Calvert	10,656	For
State Street	8,516	For
Goldman Sachs	6,462	For
John Hancock	6,217	For
TIAA	5,156	For
PENN SERIES FUNDS INC	5,100	For
Blackstone Alternative Investment Funds	3,700	For
Brinker Capital Destinations Trust	2,263	For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

12. To approve, for purposes of complying with NYSE American LLC listing standards and requirements, the issuance of the Company's common shares and common warrants pursuant to the terms of the securities purchase agreement, dated November 19, 2024, between the Company and Broadwood Partners, L.P., the Company's common shares issuable upon exercise of such common warrants.

CAPITAL STRUCTURE

Meeting held 2025-01-27.

100% fund support · no official result

FOR 100%

The 21 asset managers below cast 100% of the shares they voted on this item FOR (10,752,505 for, 0 against).

FOR: 10,752,505 (100.0%)

Largest asset managers voting on “To approve, for purposes of complying with NYSE American LLC listing standards and requirements, the issuance ” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Vanguard	8,286,793	For
Fidelity	1,408,438	For
BRIDGEWAY FUNDS INC	360,685	For
Lincoln Financial	128,800	For
Equitable	119,670	For
T. Rowe Price	66,979	For
Pacific Life	66,327	For
TIAA	62,808	For
State Street	47,331	For
ProShares	42,841	For
Northern Trust	39,931	For
Voya	38,835	For
AIG/SunAmerica	31,518	For
DWS	19,932	For
Calvert	10,656	For
Victory Capital	7,443	For
PENN SERIES FUNDS INC	5,100	For
Morgan Stanley	4,062	For
Brinker Capital Destinations Trust	2,263	For
Guggenheim	2,091	For
Nationwide	2	For

13. TO APPROVE, FOR PURPOSES OF COMPLYING WITH NYSE AMERICAN LLC LISTING STANDARDS AND REQUIREMENTS, THE ISSUANCE OF THE COMPANY'S COMMON SHARES AND COMMON WARRANTS PURSUANT TO THE TERMS OF THE SECURITIES PURCHASE AGREEMENT, DATED NOVEMBER 19, 2024, BETWEEN THE COMPANY AND BROADWOOD PARTNERS, L.P., AND THE COMPANY'S COMMON SHARES ISSUABLE UPON EXERCISE OF SUCH COMMON WARRANTS.

CAPITAL STRUCTURE

Meeting held 2025-01-27.

100% fund support · no official result

FOR 100%

The 8 asset managers below cast 100% of the shares they voted on this item FOR (3,398,353 for, 0 against).

FOR: 3,398,353 (100.0%)

Largest asset managers voting on “TO APPROVE, FOR PURPOSES OF COMPLYING WITH NYSE AMERICAN LLC LISTING STANDARDS AND REQUIREMENTS, THE ISSUANCE ” at LINEAGE CELL THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
BlackRock	2,786,683	For
Charles Schwab	416,223	For
Global X	81,445	For
QUANTITATIVE MASTER SERIES LLC	44,600	For
John Hancock	32,559	For
Bridge Builder Trust	31,143	For
Jackson National	4,400	For
apricus wealth, LLC	1,300	For

Largest LINEAGE CELL THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of LINEAGE CELL THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 228,356,290 shares outstanding at the time of that meeting.

Top LINEAGE CELL THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	RAFFLES ASSOCIATES LP	2.47%
2	COMERICA BANK	1.75%
3	GEODE CAPITAL MANAGEMENT, LLC	1.48%
4	Fidelity	1.36%
5	Vanguard	1.16%
6	DAFNA Capital Management LLC	1.10%
7	BlackRock	0.99%
8	State Street	0.54%
9	Charles Schwab	0.44%
10	Northern Trust	0.41%

Reported LINEAGE CELL THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

LINEAGE CELL THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BROADWOOD PARTNERS, L.P.	25.16%	13D
Neal C. Bradsher	21.84%	DEF14A
BlackRock	5.02%	13F
Chernett Jorey	5.01%	13G
Vanguard Group	3.91%	13F
Brian M. Culley	3.00%	DEF14A
Geode Capital	1.96%	13F
State Street	1.16%	13F
Renaissance Technologies	1.00%	13F
George A. Samuel III	0.78%	DEF14A

Percentages above are of 228,356,290 shares outstanding, as reported by LINEAGE CELL THERAPEUTICS INC. on its Form 10-Q dated 2025-05-07 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LINEAGE CELL THERAPEUTICS INC.’s 10-Q dated 2025-05-07. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At LINEAGE CELL THERAPEUTICS INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held 2025-01-27 and 2025-06-26), 120 asset managers reported how they voted in their SEC Form N-PX filings, covering 934 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2025-06-26 — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — the proposal passed with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: LINEAGE CELL THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-07-02.

LINEAGE CELL THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.